These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 9697664

  • 1. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
    Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.
    J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664
    [Abstract] [Full Text] [Related]

  • 2. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
    Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S48-54. PubMed ID: 9808143
    [Abstract] [Full Text] [Related]

  • 3. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [Abstract] [Full Text] [Related]

  • 4. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Oct; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 5. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [Abstract] [Full Text] [Related]

  • 6. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.
    Martin KJ, González E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S57-63. PubMed ID: 11689389
    [Abstract] [Full Text] [Related]

  • 7. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
    Koc H, Hoser H, Akdag Y, Kendir C, Ersoy FF.
    Int Urol Nephrol; 2019 Jul; 51(7):1261-1270. PubMed ID: 31161518
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
    Webb NJA, Lerner G, Warady BA, Dell KM, Greenbaum LA, Ariceta G, Hoppe B, Linde P, Lee HJ, Eldred A, Dufek MB.
    Pediatr Nephrol; 2017 Jul; 32(7):1221-1232. PubMed ID: 28332096
    [Abstract] [Full Text] [Related]

  • 9. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, Mohamad S, Goh BL, Shah S, Seman MR, Vaithilingam I, Ghazalli R, Rahmat K, Shaariah W, Ching CH, Oral Paricalcitol in ESRD Study Group.
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [Abstract] [Full Text] [Related]

  • 10. Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
    Staniforth ME, Cheng SC, Coyne DW.
    Clin Nephrol; 2005 Jun; 63(6):454-60. PubMed ID: 15960147
    [Abstract] [Full Text] [Related]

  • 11. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F, Yudd M.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [Abstract] [Full Text] [Related]

  • 12. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
    Biggar P, Kovarik J, Klauser-Braun R, Graf H, Müller HW, Veres A, Seidinger S, Ketteler M.
    Nephron Clin Pract; 2014 Nov; 126(1):39-50. PubMed ID: 24458019
    [Abstract] [Full Text] [Related]

  • 13. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ, Gafor AH, Yean LC, Cader R, Mohd R, Kong NC, Shah SA.
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [Abstract] [Full Text] [Related]

  • 14. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM.
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [Abstract] [Full Text] [Related]

  • 15. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.
    Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW.
    Am J Kidney Dis; 2000 Sep; 36(3):550-61. PubMed ID: 10977787
    [Abstract] [Full Text] [Related]

  • 16. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M.
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [Abstract] [Full Text] [Related]

  • 17. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
    Martin KJ, González EA, Gellens ME, Hamm LL, Abboud H, Lindberg J.
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S61-6. PubMed ID: 9808145
    [Abstract] [Full Text] [Related]

  • 18. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D.
    Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L.
    Ren Fail; 2012 Apr; 34(3):297-303. PubMed ID: 22251408
    [Abstract] [Full Text] [Related]

  • 20. Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients.
    Zheng JQ, Hou YC, Zheng CM, Lu CL, Liu WC, Wu CC, Huang MT, Lin YF, Lu KC.
    Nutrients; 2016 Nov 05; 8(11):. PubMed ID: 27827962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.